SureTrader
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/27/2018 1:29:55 AM - Followers: 149 - Board type: Free - Posts Today: 2



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

SureTrader
IDRA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
IDRA News: Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development P... 04/26/2018 07:00:00 AM
IDRA News: Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Chec... 04/17/2018 07:00:00 AM
IDRA News: Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clin... 04/16/2018 07:00:00 AM
IDRA News: BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger 04/10/2018 07:30:00 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 04/04/2018 04:57:49 PM
News News Alert: Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development P... 04/26/2018 07:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#3206   Idera Pharmaceuticals, Inc. (Idera) (NASDAQ:IDRA), a clinical-stage biopharma terry hallinan 04/27/18 01:29:55 AM
#3205   Idera Pharmaceuticals, Inc. (Idera) (NASDAQ:IDRA), a clinical-stage biopharma terry hallinan 04/27/18 01:29:53 AM
#3204   Check idra news for asco presentation youssef 04/26/18 07:29:54 PM
#3203   Youssef, I know idra very well I had 20000 terry hallinan 04/25/18 08:49:43 AM
#3202   Youssef, I know idra very well I had 20000 terry hallinan 04/25/18 08:49:42 AM
#3201   I know idra very well I had 20000 youssef 04/24/18 11:33:01 PM
#3200   The reason for me is positive a result youssef 04/24/18 11:31:20 PM
#3199   Youssef, The merger will happen terry hallinan 04/24/18 11:28:03 PM
#3198   The merger will happen it was delayed after youssef 04/24/18 11:14:01 PM
#3197   Pr0drIv3, have an idea why this is going down[/color terry hallinan 04/24/18 03:19:08 PM
#3196   Some have an idea why this is going Pr0drIv3 04/24/18 02:52:31 PM
#3195   Thanks for sharing the information here. Citrati 04/14/18 11:44:03 PM
#3194   Potential competitor SD-101 does not impress at AACR... jaybe 04/13/18 05:45:52 PM
#3193   Thanks for posting. Citrati 04/13/18 04:59:27 PM
#3192   BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Cbdpotential 04/10/18 09:31:12 AM
#3191   Well said Green week to you and yours :-) Cbdpotential 04/02/18 03:59:33 PM
#3190   Drop is overdone IMO. If holders are selling Citrati 03/28/18 10:55:28 AM
#3189   On a daily chart IDRA working on a Citrati 03/26/18 10:44:05 AM
#3188   Hope IDRA traders and investors have been watching Citrati 03/23/18 10:52:55 AM
#3187   Unless you have fortune telling ability or inside Citrati 03/19/18 12:45:09 PM
#3186   I think they will make billions , I youssef 03/07/18 09:54:18 AM
#3185   Baker Bro. position has doubled to nearly 39million Citrati 03/07/18 08:48:46 AM
#3184   There is news about the merger on swab youssef 03/06/18 06:56:05 PM
#3183   stockcharts.com/c-sc/sc?s=IDRA&p=W&yr=3&mn=0&dy=0&i=t71172375280&r=152037 Citrati 03/06/18 05:46:02 PM
#3182   LOL, 10days to knock it down and two Citrati 03/05/18 07:46:47 PM
#3181   We shall see, but I think we have Citrati 03/02/18 03:31:12 PM
#3180   Phase 3...now recruiting... jaybe 03/02/18 01:43:02 PM
#3179   Phase 3 news, looking good! Most trials don't Wolf91 03/01/18 08:49:41 AM
#3178   https://seekingalpha.com/news/3335572-idera-pharma-launches-late-stage-study-imo Citrati 03/01/18 08:30:10 AM
#3177   AACR titles posted online today... jaybe 02/21/18 08:03:18 PM
#3176   Noretreat, I don't necessarily agree with them but it terry hallinan 02/19/18 12:08:58 PM
#3175   I don't necessarily agree with them but it noretreat 02/19/18 07:16:15 AM
#3174   this is long but makes a lot of terry hallinan 02/19/18 07:11:25 AM
#3173   A very interesting read. Thanks for posting. Stockdoggy 02/16/18 02:50:01 PM
#3172   this is long but makes a lot of noretreat 02/16/18 01:58:41 PM
#3171   Up, down, up. BB's think it is time Citrati 02/16/18 10:58:06 AM
#3170   been trading heavily the past week. did noretreat 02/08/18 08:41:56 PM
#3169   Surprised no one has commented on a nice Citrati 02/07/18 12:23:08 AM
#3168   I hear you. I am not all in Citrati 02/05/18 03:01:46 PM
#3167   The question I need answered is "how sweet noretreat 02/05/18 02:45:59 PM
#3166   Yes, I believe it is certain, IMO. You Citrati 02/05/18 02:37:45 PM
#3165   When does the merger take place? Is noretreat 02/05/18 02:27:03 PM
#3164   Daily thinks the bottom could be in. See Citrati 02/05/18 10:45:30 AM
#3163   Article on TLR-9 eradicating tumors getting attention.... jaybe 02/03/18 12:21:47 PM
#3162   Anyone watching BCRX will note that it is Citrati 01/26/18 12:44:06 PM
#3161   looking pretty weak here....where is the bottom? noretreat 01/25/18 04:19:38 PM
#3160   Looks to me like it will form a Cbdpotential 01/24/18 02:42:36 PM
#3159   Weird but sweet deal looks like to me terry hallinan 01/23/18 01:31:45 PM
#3158   The deal has very nice potential synergy IMO. Citrati 01/23/18 10:04:19 AM
#3157   Looks like some traders dumped at the open noretreat 01/23/18 09:57:14 AM
PostSubject